Reimbursement

The Pharmacy Times® Reimbursement resource center provides clinical news and articles, information about reimbursement for clinical pharmacy services.

What can we help you find?
[[thumbnail_alt_text]]
Artificial intelligence will inevitably play a major role in hub services, improving efficiency and speed to therapy.
[[thumbnail_alt_text]]
Pharma companies that shift their attention to what providers, payers, and patients are asking for will profit from the growing worldwide market on preventative care.
[[thumbnail_alt_text]]
In an era of high-priced drugs, health care stakeholders continue to explore alternative pricing models that focus on the concept of value-based drug purchasing models.
[[thumbnail_alt_text]]
At minimum, they should engage in compliance risks; financial opportunities; key advocacy efforts; and program resources, structure, and value.
[[thumbnail_alt_text]]
The intention of risk evaluation and mitigation strategy programs is to ensure that the patient gets potentially dangerous drugs that are monitored appropriately.
[[thumbnail_alt_text]]
Before COVID-19, the health care industry was largely headed toward a value-based system that was shifting to focus on social determinants of health, according to Bruce Japsen, at the PQA 2020 Annual Meeting.
 
[[thumbnail_alt_text]]
Medication therapy problem category framework is the tool used to collect and evaluate medication-related issues
[[thumbnail_alt_text]]
The impact of COVID-19 on the health plan enterprise appears to be practical and functional rather than strategic and financial.
[[thumbnail_alt_text]]
Survey finds that nearly two-thirds of specialty pharmacists spend more than 15 minutes on the phone to fill 1 prescription, whereas 79% of specialty pharmacists seek additional information from clinicians at least 3 times in an average day.
[[thumbnail_alt_text]]
More than 25% of US patients have not filled a prescription or have reduced their prescribed dose because of high costs.
[[thumbnail_alt_text]]
If the majority of Americans were diagnosed with COVID-19, the total cost of hospitalizations, ventilators, and other resources could cost $654 billion.
 
[[thumbnail_alt_text]]
The relief money will be distributed on the basis of operating expenses.